key: cord-0884230-biomr3j2
authors: Chia, Po Ying; Xiang Ong, Sean Wei; Chiew, Calvin J.; Ang, Li Wei; Chavatte, Jean-Marc; Mak, Tze-Minn; Cui, Lin; Kalimuddin, Shirin; Chia, Wan Ni; Tan, Chee Wah; Ann Chai, Louis Yi; Tan, Seow Yen; Zheng, Shuwei; Pin Lin, Raymond Tzer; Wang, Linfa; Leo, Yee-Sin; Lee, Vernon J.; Lye, David Chien; Young, Barnaby Edward
title: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study
date: 2021-11-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.11.010
sha: 4016c790f83abac3e79a0ddb68a00e9af19d8dc3
doc_id: 884230
cord_uid: biomr3j2

OBJECTIVES: Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination alters virological and serological kinetics in breakthrough infections. METHODS: We conducted a multi-centre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We compared clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals. RESULTS: Out of 218 individuals with B.1.617.2 infection, 84 received a mRNA vaccine of which 71 were fully vaccinated, 130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine-breakthrough group, only 2.8% (2/71) developed severe COVID-19 requiring oxygen supplementation compared to 53.1% (69/130) in the unvaccinated group (p<0.001). Odds of severe COVID-19 following vaccination were significantly lower (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001). PCR cycle threshold values were similar between vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients, however, these titers were significantly lower against B.1.617.2 as compared with wildtype vaccine strain. CONCLUSION: The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of COVID-19 pandemic.

Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have 27 been developed but variants of concerns are worrisome, especially B.1.617.2 (Delta) which has rapidly 28 spread across the world. We aim to study if vaccination alters virological and serological kinetics in 29 breakthrough infections. 30

We conducted a multi-centre retrospective cohort study of patients in Singapore who had received a 32 For descriptive analysis, data were presented as median (interquartile range (IQR)) for continuous 121 parameters and frequency (percentage) for categorical variables. Chi-square and Fisher's exact tests 122 were used to compared categorical variables, while for continuous variables, t-test was used for 123 normal data and Mann-Whitney U test for non-normal data. For asymptomatic patients, the day of 124 confirmatory COVID-19 diagnosis was denoted as day one of illness. For symptomatic patients, day of 125 symptom onset or the day of confirmatory COVID-19 diagnosis, whichever earlier, was denoted as day 126 one of illness. 127

Previously reported risk factors for disease severity [21] were evaluated and included in a multivariate 128 logistic regression model [22] . 

In line with Singapore's national vaccination strategy wherein older adults were prioritized, our 155 vaccine-breakthrough cohort was of significantly older age; median age of 56 years (IQR:39-64) versus 156 39.5 (IQR:30-58) (p<0.001) ( Table 1 ). Other baseline demographics were similar. 157

Vaccine-breakthrough patients were significantly more likely to be asymptomatic (28.2% versus 9.2%, 158 p<0.001); and if symptomatic, had fewer number of symptoms (Table 1) Table T1) . There are several limitations to our study. Firstly, we only compared vaccine-breakthrough infections 234 with unvaccinated COVID-19 patients. We did not study vaccinated individuals who had similar 235 exposure risk but did not develop COVID-19 infection. We thus could not evaluate vaccine efficacy 236 against asymptomatic infection. We also did not have detailed epidemiologic data to study the effect 237 of vaccination on preventing secondary transmission. 238

Secondly, we could only obtain serologic tests after infection since patients were recruited after 239 confirmation of infection. While active contact tracing and case finding in Singapore resulted in early 240 J o u r n a l P r e -p r o o f identification of most COVID-19 cases, the first available serologic result was at a median of 2 (IQR: 3) days of illness and antibody levels are likely to already have been boosted by natural infection. We 242 thus could not evaluate underlying immunologic mechanisms behind vaccine-breakthrough infection, 243 e.g., diminished neutralizing antibody level or impaired cellular immunity. Further study should 244 compare similarly exposed vaccinated individuals who develop breakthrough infection with those who 245 do not, to elucidate the underlying drivers of susceptibility, which may enlighten us on how to optimize 246 protection (e.g., through enhanced/boosted dosing schedules). 247

Thirdly, PCR testing was not standardized in a centralized laboratory, but was performed using various J o u r n a l P r e -p r o o f 

Safety and Efficacy 315 of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19 317 Vaccine in a Nationwide Mass Vaccination Setting

Association Between 319 Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 320 Infections Among Health Care Workers

Efficacy and Safety of the 322 mRNA-1273 SARS-CoV-2 Vaccine

Impact and effectiveness 324 of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and 325 deaths following a nationwide vaccination campaign in Israel: an observational study using national 326 surveillance data

Interim findings from first-328 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national 329 prospective cohort study

Impact of 331 vaccination on new SARS-CoV-2 infections in the United Kingdom

Estimated 333 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Detection of a 335 SARS-CoV-2 variant of concern in South Africa

Lee Serial intervals observed in SARS-CoV-2 B.1.617.2 337 variant cases

Robertson SARS-CoV-2 Delta VOC in Scotland: 341 demographics, risk of hospital admission, and vaccine effectiveness

Evidence for increased 345 breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA

Variants of concern 348 are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington 349 State

Updates on COVID-19 (Coronavirus Disease 2019) Local Situation

COVID-19 therapies and vaccine landscape

A SARS-CoV-2 surrogate virus 354 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Treatment Guidelines for COVID-19

Conditions/Pages/COVID-19.aspx>, 2021

Young Risk Factors for Severe Disease and Efficacy 362 of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-363 Regression Analysis

FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression. Statistical 365 Software Components S456948, Boston College Department of Economics, revised 25

Prevention and 368 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

371 Shedding of Infectious SARS-CoV-2 Despite Vaccination

Impact of 373 Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Effectiveness of 376 COVID-19 vaccines against the B.1.617.2 variant

Robertson SARS-CoV-2 Delta VOC in Scotland: 378 demographics, risk of hospital admission, and vaccine effectiveness

Viral 381 genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

Initial report of 384 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine